Fig. 1From: Transarterial chemoembolization with molecular targeted therapies plus camrelizumab for recurrent hepatocellular carcinomaFlow diagram of patient enrollment. TACE, Transarterial chemoembolization; TACE-TC, TACE plus molecular targeted therapies combined with camrelizumab; TACE-T, TACE plus molecular targeted therapiesBack to article page